A nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal manner
The KRAS oncoprotein is a frequent tumor driver in lung, pancreatic, and colorectal cancers and has proven to be a challenging pharmaceutical target. The first KRAS-targeted therapeutics are now being tested in clinical trials but the consequences of preferentially targeting the GDP or GTP state of...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2025
|
| In: |
Molecular oncology
Year: 2025, Jahrgang: 19, Heft: 11, Pages: 3266-3286 |
| ISSN: | 1878-0261 |
| DOI: | 10.1002/1878-0261.70061 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/1878-0261.70061 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.70061 
|
| Verfasserangaben: | Jonas N. Kapp, Wouter P.R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy-Davidescu, Elodie Richard, Marie-Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria and Andreas Plückthun |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1939489059 | ||
| 003 | DE-627 | ||
| 005 | 20251110133711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251027s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/1878-0261.70061 |2 doi | |
| 035 | |a (DE-627)1939489059 | ||
| 035 | |a (DE-599)KXP1939489059 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kapp, Jonas |e VerfasserIn |0 (DE-588)1379978254 |0 (DE-627)1939489547 |4 aut | |
| 245 | 1 | 2 | |a A nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal manner |c Jonas N. Kapp, Wouter P.R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy-Davidescu, Elodie Richard, Marie-Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria and Andreas Plückthun |
| 264 | 1 | |c 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 21 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Zuerst veröffentlicht: 15. Juni 2025 | ||
| 500 | |a Gesehen am 27.10.2025 | ||
| 520 | |a The KRAS oncoprotein is a frequent tumor driver in lung, pancreatic, and colorectal cancers and has proven to be a challenging pharmaceutical target. The first KRAS-targeted therapeutics are now being tested in clinical trials but the consequences of preferentially targeting the GDP or GTP state of KRAS and the relevance of RAS nanoclustering have remained unclear. Here we report a Designed Ankyrin Repeat Protein (DARPin) that recognizes the RAS switch I/II region with low nm affinity, independently of the nucleotide bound (GDP- or GTP state). This DARPin, termed ‘784_F5’, occupies the effector recognition lobe, resulting in interference with SOS-mediated activation, RAS downstream effector interactions, and KRAS nanoclustering. Consequently, this anti-RAS DARPin potently blocks downstream signaling, leading to a strong reduction in proliferation and anchorage-independent growth in RAS-dependent cell lines. We showed that the expression of ‘784_F5’, the pan-RAS, nucleotide-independent DARPin can lead to tumor regression in a colorectal xenograft model which may hold promise for further investigation and development. | ||
| 650 | 4 | |a cancer | |
| 650 | 4 | |a Designed Ankyrin Repeat Protein | |
| 650 | 4 | |a drug development | |
| 650 | 4 | |a oncogene | |
| 650 | 4 | |a RAS | |
| 650 | 4 | |a small GTPase | |
| 700 | 1 | |a Verdurmen, Wouter P. R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schaefer, Jonas V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kopra, Kari |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nagy-Davidescu, Gabriela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Richard, Elodie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nokin, Marie-Julie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ernst, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tamaskovic, Rastislav |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schwill, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Degen, Ralph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scholl, Claudia |d 1971- |e VerfasserIn |0 (DE-588)128803533 |0 (DE-627)380643197 |0 (DE-576)187440271 |4 aut | |
| 700 | 1 | |a Santamaria, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Plückthun, Andreas |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular oncology |d Hoboken, NJ : John Wiley & Sons, Inc., 2007 |g 19(2025), 11, Seite 3266-3286 |h Online-Ressource |w (DE-627)531199800 |w (DE-600)2322586-5 |w (DE-576)271586621 |x 1878-0261 |7 nnas |a A nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal manner |
| 773 | 1 | 8 | |g volume:19 |g year:2025 |g number:11 |g pages:3266-3286 |g extent:21 |a A nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal manner |
| 856 | 4 | 0 | |u https://doi.org/10.1002/1878-0261.70061 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.70061 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251027 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 128803533 |a Scholl, Claudia |m 128803533:Scholl, Claudia |d 50000 |e 50000PS128803533 |k 0/50000/ |p 12 | ||
| 999 | |a KXP-PPN1939489059 |e 4791932609 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Zuerst veröffentlicht: 15. Juni 2025","Gesehen am 27.10.2025"],"person":[{"role":"aut","given":"Jonas","family":"Kapp","display":"Kapp, Jonas","roleDisplay":"VerfasserIn"},{"given":"Wouter P. R.","role":"aut","roleDisplay":"VerfasserIn","family":"Verdurmen","display":"Verdurmen, Wouter P. R."},{"display":"Schaefer, Jonas V.","family":"Schaefer","roleDisplay":"VerfasserIn","role":"aut","given":"Jonas V."},{"role":"aut","given":"Kari","roleDisplay":"VerfasserIn","family":"Kopra","display":"Kopra, Kari"},{"role":"aut","given":"Gabriela","display":"Nagy-Davidescu, Gabriela","family":"Nagy-Davidescu","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Richard, Elodie","family":"Richard","given":"Elodie","role":"aut"},{"family":"Nokin","display":"Nokin, Marie-Julie","roleDisplay":"VerfasserIn","role":"aut","given":"Marie-Julie"},{"family":"Ernst","display":"Ernst, Patrick","roleDisplay":"VerfasserIn","given":"Patrick","role":"aut"},{"display":"Tamaskovic, Rastislav","family":"Tamaskovic","roleDisplay":"VerfasserIn","given":"Rastislav","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Schwill","display":"Schwill, Martin","given":"Martin","role":"aut"},{"given":"Ralph","role":"aut","family":"Degen","display":"Degen, Ralph","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Scholl, Claudia","family":"Scholl","role":"aut","given":"Claudia"},{"roleDisplay":"VerfasserIn","family":"Santamaria","display":"Santamaria, David","role":"aut","given":"David"},{"role":"aut","given":"Andreas","family":"Plückthun","display":"Plückthun, Andreas","roleDisplay":"VerfasserIn"}],"title":[{"title":"A nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal manner","title_sort":"nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal manner"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1002/1878-0261.70061"],"eki":["1939489059"]},"language":["eng"],"physDesc":[{"extent":"21 S.","noteIll":"Illustrationen"}],"recId":"1939489059","name":{"displayForm":["Jonas N. Kapp, Wouter P.R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy-Davidescu, Elodie Richard, Marie-Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria and Andreas Plückthun"]},"relHost":[{"note":["Gesehen am 25.06.20"],"title":[{"title":"Molecular oncology","title_sort":"Molecular oncology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"id":{"eki":["531199800"],"zdb":["2322586-5"],"issn":["1878-0261"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"531199800","part":{"text":"19(2025), 11, Seite 3266-3286","issue":"11","extent":"21","year":"2025","pages":"3266-3286","volume":"19"},"name":{"displayForm":["Federation of European Biochemical Societies"]},"origin":[{"publisher":"John Wiley & Sons, Inc. ; Elsevier","dateIssuedDisp":"2007-","dateIssuedKey":"2007","publisherPlace":"Hoboken, NJ ; Amsterdam [u.a.]"}],"disp":"A nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal mannerMolecular oncology","pubHistory":["1.2007 -"]}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"2025"}]} | ||
| SRT | |a KAPPJONASVNUCLEOTIDE2025 | ||